Immunovant (IMVT) Long-Term Investments (2019)

Immunovant's (IMVT) quarterly Long-Term Investments came in at $116.0 million in Q3 2019, up 0.59% on a QoQ basis from $115.3 million in Q2 2019.

Immunovant (IMVT) Long-Term Investments (2019) Analysis & Trends

Immunovant (IMVT) has 1 years of Long-Term Investments data on file, last reported at $116.0 million in Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.79 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 9.83 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 372.10 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 22.17 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Immunovant 8.63 Bn 7.83 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2019 116.02 Mn
Jun 30, 2019 115.34 Mn